Tag:
Zostavax
Latest Headlines
Latest Headlines
The 20 top-selling vaccines in H1 2012
As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales. Take a look at the full list >>
Merck expands packaging plant to take on more vaccines
With increased production and growing supplies, the company hopes to regain some of the momentum with Zostavax that was lost when production issues derailed plans in 2006.
Shingles shot safe and well-tolerated, study finds
Shingles can lead to post-herpetic pain and other issues in older people, and the vaccine, which halves the chance of severe attacks of shingles, is safe and well-tolerated in this group, a new study finds.
Innovative construction project boosts Merck's Zostavax manufacturing
It has taken 6 years, but with a significant manufacturing expansion, Merck has gotten its issues addressed for its shingles vaccine Zostavax.
With Zostavax supplies restored, Merck aims for revival
After manufacturing problems constricted supplies for several years, the U.S.-based drugmaker has filled back orders and restored ongoing supplies, clearing the way for a renewed sales push.
Study: No benefit for Merck's zoster booster
A paper presented to the American Academy of Dermatology looked at the effectiveness of a booster shot of a VZV vaccine.
Shingles vaccination levels fall short of expectations
Five years ago, Merck gained FDA approval for its shingles prevention vaccine Zostavax. The agency recently expanded that approval to adults 50 years and older. Yet vaccination rates remain low due
FDA approves Merck's Zostavax for more adults
Three months after the CDC recommended all adults over the age of 60 receive Merck's Zostavax vaccine, the FDA has approved the shingles preventative for use in adults ages 50 to 59. The FDA approved
Virus present up to one month after Zostavax immunization
Some patients inoculated with Zostavax, Merck's shingles vaccine, shed the virus used for the vaccine through their saliva for one month after immunization, according to a researcher from the
Merck's Zostavax halves risk of shingles
Although shingles isn't cureable, a retrospective study has found that Merck's Zostavax vaccine can cut a person's risk of of developing the illness by 55 percent. It is the only shingles vax
